Leap Therapeutics Announces $58.9 Million Private Placement Led by Winklevoss Capital to Launch Digital Asset Treasury Strategy

Reuters10-06
Leap <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces $58.9 Million Private Placement Led by Winklevoss Capital to Launch <a href="https://laohu8.com/S/DAAQU">Digital Asset</a> Treasury <a href="https://laohu8.com/S/MSTR">Strategy</a>

Leap Therapeutics Inc. (Nasdaq: LPTX), a biotechnology company specializing in targeted and immuno-oncology therapies, has announced a $58.88 million private placement led by Winklevoss Capital. The financing involves the sale of approximately 95.8 million shares of common stock or pre-funded warrants, along with additional warrants to purchase about 71.9 million shares at an exercise price of $0.5335 per share. The aggregate exercise price per unit is set at $0.61439. The funds raised will support Leap's newly initiated digital asset treasury strategy. Parcrest is serving as the placement agent, with Morgan, Lewis & Bockius LLP advising Leap and Cooley LLP advising Winklevoss Capital. The closing of the private placement is expected soon, pending customary closing conditions. Leap plans to provide further updates on its treasury activities in the near term.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Leap Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE90771) on October 06, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment